{"id":55528,"date":"2023-01-04T10:50:34","date_gmt":"2023-01-04T10:50:34","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55528"},"modified":"2023-01-04T10:50:34","modified_gmt":"2023-01-04T10:50:34","slug":"srdan-verstovsek-ash-2022-momelotinib-long-term-safety-in-myelofibrosis-disease-analysis-of-simplify-1-simplify-2-and-momentum-trials","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematological-malignancies\/conference-hub\/srdan-verstovsek-ash-2022-momelotinib-long-term-safety-in-myelofibrosis-disease-analysis-of-simplify-1-simplify-2-and-momentum-trials\/","title":{"rendered":"Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials"},"content":{"rendered":"
Momelotinib, an oral JAK1\/JAK2\/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis.\u00a0<\/span>In this touchONCOLOGY interview, we speak with<\/span> Prof. Srdan Verstovsek <\/b>(MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of momelotinib that characterized its long-term safety, with pooled data from the three trials, which represented a spectrum of myelofibrosis disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages.<\/span><\/p>\n The abstract entitled \u2018Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)<\/a><\/span>\u2019 (Abstract #4348) was presented at 64th ASH Annual Meeting and Exposition<\/a>, December 10-13 2022, New Orleans, LA, USA<\/span><\/p>\n Disclosures<\/b>: Srdan Verstovsek has nothing to disclose in relation to this video interview.<\/span><\/p>\n Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.<\/span><\/p>\n\n